Literature DB >> 3141344

The penetration of fleroxacin into bronchial mucosa.

R Wise1, D Honeybourne, J M Andrews, J P Ashby.   

Abstract

Twenty patients undergoing fibreoptic endoscopy received 400 mg of fleroxacin once a day for four days. Bronchial biopsies were performed 2.7-5.9 h following the final dose of fleroxacin. A microbiological assay was used to determine the levels of fleroxacin in serum and biopsy material. The serum levels of fleroxacin ranged from 3.9-12.5 mg/l (mean 8.4, S.D. 2.4). In all but one patient the bronchial mucosa level exceeded that in serum, the range being 5.9-19 mg/l (mean 12.8, S.D. 3.3). The mean percentage penetration into bronchial mucosa over the period of the study was 158% (S.D. 41.2%). The therapeutic implications are discussed.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3141344     DOI: 10.1093/jac/22.2.203

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  7 in total

1.  Factors influencing elimination and distribution of fleroxacin: metaanalysis of individual data from 10 pharmacokinetic studies.

Authors:  B G Reigner; H A Welker
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

2.  Fleroxacin pharmacokinetics in patients with liver cirrhosis.

Authors:  R A Blouin; B A Hamelin; D A Smith; T S Foster; W J John; H A Welker
Journal:  Antimicrob Agents Chemother       Date:  1992-03       Impact factor: 5.191

3.  Pharmacokinetics of [18F]fleroxacin in patients with acute exacerbations of chronic bronchitis and complicated urinary tract infection studied by positron emission tomography.

Authors:  A J Fischman; E Livni; J W Babich; N M Alpert; A Bonab; S Chodosh; F McGovern; P Kamitsuka; Y Y Liu; R Cleeland; B L Prosser; J A Correia; R H Rubin
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

4.  Pharmacokinetics of [18F]fleroxacin in healthy human subjects studied by using positron emission tomography.

Authors:  A J Fischman; E Livni; J Babich; N M Alpert; Y Y Liu; E Thom; R Cleeland; B L Prosser; J A Correia; H W Strauss
Journal:  Antimicrob Agents Chemother       Date:  1993-10       Impact factor: 5.191

Review 5.  Fleroxacin. A review of its pharmacology and therapeutic efficacy in various infections.

Authors:  J A Balfour; P A Todd; D H Peters
Journal:  Drugs       Date:  1995-05       Impact factor: 9.546

Review 6.  Fluoroquinolone antimicrobial agents.

Authors:  J S Wolfson; D C Hooper
Journal:  Clin Microbiol Rev       Date:  1989-10       Impact factor: 26.132

7.  Pharmacokinetics of 18F-labeled fleroxacin in rabbits with Escherichia coli infections, studied with positron emission tomography.

Authors:  A J Fischman; E Livni; J Babich; N M Alpert; Y Y Liu; E Thom; R Cleeland; B L Prosser; R J Callahan; J A Correia
Journal:  Antimicrob Agents Chemother       Date:  1992-10       Impact factor: 5.191

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.